PRTA

Prothena Corporation plc (NASDAQ:PRTA) last week reported its latest quarterly results, which makes it a good time for investors to dive in and see if the business is performing in line with expectations. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. Taking into account the latest results, the current consensus from Prothena's six analysts is for revenues of US$83.3m in 2026. This would reflect a major 44% increase on its revenue over the past 12 months. Earnings are expected to improve, with Prothena forecast to report a statutory profit of US$0.047 per share. In the lead-up to this report, the analysts had been modelling revenues of US$92.0m and earnings per share (EPS) of US$0.25 in 2026. From this we can that sentiment has definitely become more bearish after the latest results, leading to lower revenue forecasts and a large cut to earnings per share estimates. View our latest analysis for Prothena The analysts made no major changes to their price target of US$21.40, suggesting the downgrades are not expected to have a long-term impact on Prothena's valuation. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. Currently, the most bullish analyst values Prothena at US$36.00 per share, while the most bearish prices it at US$8.00. With such a wide range in price targets, analysts are almost certainly betting on widely divergent outcomes in the underlying business. As a result it might not be a great idea to make decisions based on the consensus price target, which is after all just an average of this wide range of estimates. These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Prothena's past performance and to peers in the same industry. For example, we noticed that Prothena's rate of growth is expected to accelerate meaningfully, with revenues forecast...

DUBLIN 2, Ireland (AP) — Prothena Corp. (PRTA) on Thursday reported first-quarter earnings of $32.7 million. The Dublin 2, Ireland-based company said it had net income of 60 cents per share. Earnings, adjusted for restructuring gains, were 52 cents per share. The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 31 cents per share. The drug developer posted revenue of $51.1 million in the period. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on PRTA at https://www.zacks.com/ap/PRTA

Net cash provided by operating and investing activities was $28.9 million for the first quarter of 2026; quarter-end cash and restricted cash position was $330.3 million Prothena updates projected full year 2026 net cash used in operating and investing actives to be $18 to $23 million (versus prior guidance $50 to $55 million) and expects to end the year with approximately $273 million (midpoint) in cash, cash equivalents and restricted cash Novo Nordisk obtained Fast Track designation from the U.S. FDA for coramitug (PRX004) for the treatment of ATTR amyloidosis with cardiomyopathy and paid Prothena a $50 million clinical milestone payment related to Phase 3 enrollment Roche presented several clinical updates supporting the potential of prasinezumab for the treatment of Parkinson’s disease at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD™ 2026) Prothena has completed the Phase 1 study for PRX019. Prothena could potentially earn a $55 million clinical milestone payment if Bristol Myers Squibb decides to advance the program; BMS decision expected by year-end 2026 Prothena initiated a share repurchase program to be conducted in 2026 for up to $100 million if deemed appropriate DUBLIN, May 07, 2026--(BUSINESS WIRE)--Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported financial results for the first quarter of 2026 and provided business highlights. "In the quarter we were encouraged by updates on our partnered Phase 3 clinical programs. Roche delivered several presentations highlighting the potential of prasinezumab for Parkinson’s disease at AD/PD 2026, including a ‘time saved’ analysis demonstrating approximately two years in delay of disease progression over a five year period from the PASADENA open-label extension study, longer-term data from the PADOVA open-label extension study showing a sustained effect of prasinezumab on disease progression, and exploratory biomarker analyses of the PADOVA trial suggesting that prasinezumab may impact the underlying disease biology. Novo Nordisk recently obtained Fast Track designation from the U.S. FDA for coramitug in ATTR-CM and delivered $50 million to Prothena upon achievement of a Phase 3 clinical milestone,"...

Prothena Corporation PRTA reported first-quarter 2026 adjusted earnings per share (excluding restructuring costs) of 52 cents. The Zacks Consensus Estimate was a loss of 31 cents per share. In the year-ago quarter, the company had incurred a loss of $1.12 per share. The bottom line was boosted by higher revenues resulting from a milestone payment from Novo Nordisk NVO. Revenues totaled $51.1 million compared with $2.8 million in the year-ago quarter. The top line primarily comprises collaboration revenues and milestone payments. First-quarter 2026 revenues were primarily driven by a $50.0 million milestone payment from NVO tied to the ongoing late-stage study of coramitug, along with collaboration revenues from Bristol Myers Squibb BMY related to the partial fulfillment of the company’s phase I study obligations for PRX019. Prothena’s shares have gained 10.1% in the year so far against the industry’s decline of 0.2%. Image Source: Zacks Investment Research Research and development (R&D) expenses decreased 75.2% to $12.6 million from $50.8 million in the prior-year period, primarily driven by lower clinical trial, personnel, manufacturing and consulting expenses. General and administrative (G&A) expenses decreased 28% to $12.7 million from $17.6 million in the year-ago period, mainly due to lower consulting and personnel expenses. As of March 31, 2026, Prothena had $330.3 million in cash, cash equivalents and restricted cash, compared with $308.4 million as of Dec. 31, 2025. The company had no debt at the end of the first quarter. Prothena Corporation plc price-consensus-eps-surprise-chart | Prothena Corporation plc Quote Prothena lowered its guidance for full-year 2026 net cash used in operating and investing activities to $18-$23 million from $50-$55 million. The company now expects to end 2026 with approximately $273 million in cash, cash equivalents and restricted cash at the midpoint, up $18 million from the previous midpoint guidance of $255 million. The improved cash outlook was primarily driven by the milestone payment from Novo Nordisk tied to the advancement of coramitug, partially offset by approximately $15 million used for share repurchases through April 30, 2026, liabilities related to discontinued programs and increased investment in preclinical programs. The updated outlook for net cash used in operating and investing activities is primarily b...

DUBLIN, April 30, 2026--(BUSINESS WIRE)--Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its first quarter 2026 financial results on Thursday, May 7, 2026, after the close of the U.S. financial markets. Consistent with past practice, the Company will not be conducting a conference call in conjunction with the financial results release on May 7. About Prothena Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothena’s pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including Parkinson’s disease, ATTR amyloidosis with cardiomyopathy, Alzheimer’s disease, Amyotrophic lateral sclerosis (ALS) and a number of other neurodegenerative diseases. Prothena is developing and applying CYTOPE®, a novel technology that incorporates a cell-internalizing domain to drive efficient cytosolic delivery with highly specific marcomolecular effectors. For more information, please visit the Company’s website at www.prothena.com and follow the Company on X (formerly Twitter) @ProthenaCorp. View source version on businesswire.com: https://www.businesswire.com/news/home/20260430688502/en/ Contacts Mark Johnson, CFA Senior Vice President, Head of Investor Relations and Corporate Communications 650-837-8550 [email protected] [email protected]

It has been about a month since the last earnings report for Sarepta Therapeutics (SRPT). Shares have added about 24.2% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Sarepta Therapeutics due for a pullback? Well, first let's take a quick look at the most recent earnings report in order to get a better handle on the recent drivers for Sarepta Therapeutics, Inc. before we dive into how investors and analysts have reacted as of late. Sarepta reported a fourth-quarter 2025 adjusted loss of $3.58 per share, wider than the Zacks Consensus Estimate of a loss of 71 cents. This higher-than-anticipated loss was attributed to an increase in operating expenses incurred during the quarter. In the year-ago period, the company posted an adjusted EPS of $1.91. The adjusted figures exclude depreciation and amortization costs, stock-based compensation expenses, gains on strategic investments, losses on debt extinguishment and restructuring charges. Including these items, the loss during the quarter was $3.93 against an EPS of $1.50 in the year-ago period. Sarepta recorded total revenues of $442.9 million, down nearly 33% year over year. This downtick was due to lower sales of Elevidys. The reported figure beat the Zacks Consensus Estimate of $408.5 million. Product revenues fell 42% year over year to $369.6 million. The company recorded $259 million from the product sales of its three PMO therapies, up 2% year over year. The figure missed the Zacks Consensus Estimate of $270 million. Sarepta generated $110 million from Elevidys sales, down more than 71% year over year, primarily due to its decision to suspend shipments to non-ambulatory patients in June 2025 amid safety concerns. The therapy’s sales missed the Zacks Consensus Estimate of $114 million. SRPT recorded approximately $73.3 million in collaboration and other revenues, compared to $20.3 million in the year-ago period. This uptick was mainly due to higher contract manufacturing revenues, driven by higher volume of shipments of Elevidys to Roche. Adjusted research and development (R&D) expenses totaled $308.1 million, up 78% year over year. This upside is primarily due to an increase in milestone expenses made toward pipeline development during the quarter. Adjusted selling, general & administrative (SG&A) expenses declined 20% to...

It has been about a month since the last earnings report for Jazz Pharmaceuticals (JAZZ). Shares have lost about 3.9% in that time frame, outperforming the S&P 500. But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is Jazz due for a breakout? Well, first let's take a quick look at its latest earnings report in order to get a better handle on the recent catalysts for Jazz Pharmaceuticals PLC before we dive into how investors and analysts have reacted as of late. Jazz Pharmaceuticals reported fourth-quarter 2025 adjusted earnings per share (EPS) of $6.64, which beat the Zacks Consensus Estimate of $6.62. Earnings rose 2% year over year. Total revenues rose 10% year over year to $1.2 billion, which beat the Zacks Consensus Estimate of $1.18 billion. Net product sales increased 10.5% year over year to $1.13 billion. The reported figure beat both the Zacks Consensus Estimate and our model estimate, each of which stood at $1.11 billion. Jazz recorded about $56 million in royalty revenues from high-sodium oxybate authorized generic (AG), up 1% year over year. The metric beat the Zacks Consensus Estimate of $53 million and our model estimate of $51 million. Other royalties and contract revenues were about $10 million, up 28% from the year-ago period levels. Sales of Jazz’s neuroscience products rose more than 8% year over year to $792 million. Net product sales for the combined oxybate business (Xyrem + Xywav) rose 12% to $503 million. This combined figure beat both the Zacks Consensus Estimate of $481 million and our model estimates of $485 million. Sales of Xyrem declined more than 23% year over year to $37.8 million, primarily due to patients switching to Xywav and the launch of AGs in 2023. Xywav recorded sales of more than $465 million in the quarter, reflecting 16% year-over-year growth. This upside can be attributed to the encouraging uptake of the drug in narcolepsy and IH indications. This drug is currently Jazz’s most extensive product by net sales. Sales of Epidiolex/Epidyolex rose 4% to $287 million. Per Jazz, the drug’s sales growth was negatively impacted by higher-than-normal inventory levels in the year-ago period. This likely caused Epidiolex sales to miss the Zacks Consensus Estimate of $297 million and our model estimate of $300 million. Despite this soft performance, the drug a...

Prothena Corporation PRTA reported fourth-quarter 2025 adjusted loss per share (excluding restructuring costs) of 45 cents, in line with the Zacks Consensus Estimate. In the year-ago quarter, the company had incurred a loss of $1.08 per share. Revenues totaled $0.02 million, missing the Zacks Consensus Estimate of $3.0 million. Prothena had recorded revenues of $2.1 million in the year-ago quarter. The top line primarily comprises collaboration revenues from Bristol Myers Squibb BMY. Over the past year, Prothena’s shares have lost 42% against the industry’s growth of 18.8%. Image Source: Zacks Investment Research Research and development expenses plunged 71% year over year to $14.6 million, driven by reduced clinical trial, manufacturing, personnel and consulting costs. General and administrative expenses were $12.6 million, down 25% year over year. As of Dec. 31, 2025, Prothena had $308.4 million in cash, cash equivalents and restricted cash, compared with $331.7 million as of Sept. 30, 2025. It had no debt. For 2025, Prothena reported total revenues of $9.7 million, which declined 93% year over year. For full-year 2025, the company recorded a net loss of $3.97 per share, wider than a loss of $2.27 per share in 2024. The company expects 2026 net cash burn from operating and investing activities to be in the range of $50 million-$55 million. It expects the year-end cash, cash equivalents and restricted cash midpoint to be approximately $255 million. Net loss for 2026 is projected to be in the $67 million to $72 million range. Prothena expects to earn up to $105 million as clinical milestone payments tied to the advancement of coramitug by Novo Nordisk NVO and PRX019 by BMY in 2026. Prothena Corporation plc price-consensus-chart | Prothena Corporation plc Quote Prothena is developing prasinezumab in collaboration with Roche RHHBY for the treatment of Parkinson’s disease. Roche is evaluating prasinezumab in an ongoing late-stage PARAISO study for early-stage Parkinson's disease, with primary completion expected in 2029. Roche expects peak sales potential of greater than $3.5 billion (unadjusted) of prasinezumab. Novo Nordisk had earlier acquired Prothena’s clinical-stage antibody, Coramitug (formerly PRX004), a potential first-in-class amyloid depleter antibody for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM). NVO is evaluating the candidate...

This article first appeared on GuruFocus. Net Cash Used in Operating and Investing Activities: $163.7 million, favorable to guidance range of $170 to $178 million. Net Loss: $244.1 million, in line with guidance range of $240 to $248 million. Cash and Restricted Cash: $308.4 million as of December 31, 2025, favorable to guidance of $298 million. Ordinary Shares Outstanding: 53.8 million as of February 12, 2026. Debt: Zero debt, maintaining a simple capital structure. 2026 Financial Guidance - Net Cash Used: Expected to be between $50 to $55 million. 2026 Financial Guidance - Year-End Cash: Approximately $255 million in cash and restricted cash. 2026 Estimated Net Loss: $67 to $72 million, including $24 million of non-cash share-based compensation expenses. Potential 2026 Milestone Payments: Up to $105 million from strategic partners. Warning! GuruFocus has detected 3 Warning Signs with PRTA. Is PRTA fairly valued? Test your thesis with our free DCF calculator. Release Date: February 19, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Prothena Corp PLC (NASDAQ:PRTA) advanced two partner programs, pacilizumab andrame, into phase 3 clinical trials in 2025. Roche's phase 3 Pariio trial for Parkinson's disease and Novo Nordisk's phase 3 Cleopatra trial for ATTRCM are significant advancements. Prothena's collaborations with Bristol-Myers Squibb progressed, with BMS 986-446 obtaining fast track designation from the US FDA for Alzheimer's treatment. The company has a strong cash position with $308.4 million in cash and restricted cash as of year-end 2025. Prothena is eligible for up to $105 million in clinical milestone payments in 2026 from its partnerships with large pharmaceutical companies. Primary completion dates for key partnered program trials, such as Pariio and Cleopatra, are not expected until 2029, indicating a long wait for potential results. The company's net loss for 2025 was $244.1 million, which is substantial despite being in line with guidance. Prothena's PRX 12 showed non-competitive RAE rates compared to FDA-approved anti-A beta antibodies. The company faces significant competition in the Alzheimer's treatment space, with larger and more advanced competitors. Prothena's 2026 financial guidance does not include potential milestone payments, indicating uncertainty in revenue realization. Q:...

DUBLIN (AP) — DUBLIN (AP) — Prothena Corp. (PRTA) on Thursday reported a loss of $21.6 million in its fourth quarter. On a per-share basis, the Dublin-based company said it had a loss of 40 cents. Losses, adjusted for restructuring gains, came to 44 cents per share. The results exceeded Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 45 cents per share. The drug developer posted revenue of $21,000 in the period. For the year, the company reported a loss of $244.1 million, or $4.53 per share. Revenue was reported as $9.7 million. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on PRTA at https://www.zacks.com/ap/PRTA

Partner programs advanced to late-stage trials: Roche’s prasinezumab (PARAISO) and Novo Nordisk’s coramitug (CLEOPATTRA) moved into Phase 3 (≈900 and ≈1,280 patients respectively, primary completions ~2029) after supportive Phase 2 data — including a reported ~40% MDS‑UPDRS part 3 reduction in a levodopa subgroup for prasinezumab (nominal p=0.0177) and a 48% NT‑proBNP reduction for coramitug (p=0.0017). Sharply reduced 2026 cash burn guidance but milestones excluded: Prothena used $163.7M in cash for operations/investing in 2025, ended the year with $308.4M and no debt, and now guides to only $50–55M net cash use in 2026 with ~ $255M expected year‑end cash, noting this outlook excludes up to $105M of potential partner clinical milestones. Wholly owned R&D: CYTOPE progress and PRX012 pivot: The CYTOPE intracellular‑targeting platform showed promising preclinical CNS activity (anti‑phospho TDP‑43 program for ALS), while anti‑Aβ PRX012 showed meaningful amyloid reductions but non‑competitive ARIA‑E rates, prompting development of a PRX012‑TfR approach and partner discussions. Interested in Prothena Corporation plc? Here are five stocks we like better. Prothena (NASDAQ:PRTA) used its fourth-quarter and full-year 2025 results call to highlight partner-driven clinical momentum, updates from its wholly owned preclinical portfolio, and a sharper cash burn outlook for 2026. Management repeatedly emphasized that Prothena’s pipeline is primarily advanced through collaborations and that the company is focused on “captur[ing] the value embedded in our clinical partnerships,” while continuing to build optionality through platform and preclinical work. President and CEO Gene Kinney said 2025 brought “significant progress” in the company’s clinical pipeline, calling out two partner programs that moved into phase 3. → Corning’s Surprise AI Boom: Is It Already Too Late to Buy? Roche advanced prasinezumab into the phase 3 PARAISO trial in early Parkinson’s disease, which is designed to enroll approximately 900 participants and has a primary completion expected in 2029. Chief Development Officer Chad Swanson described prasinezumab as a humanized IgG1 monoclonal antibody designed to bind aggregated alpha-synuclein and potentially slow Parkinson’s progression by blocking accumulation and propagation of toxic aggregates. Swanson said Roche’s phase 3 decision was informed by result...

Transitioned to a Phase III-focused clinical stage through partners Roche and Novo Nordisk, targeting large-market indications in Parkinson's and ATTR-CM. Attributed the advancement of prasinezumab to Phase III based on Phase II data showing a 40% relative reduction in motor progression for patients on stable levodopa. Pivoted the wholly-owned PRX012 Alzheimer's program toward a transferrin receptor (TfR) fusion approach to address non-competitive ARIA-E safety rates observed in Phase I. Introduced CYTOPE technology as a strategic platform to reach 'undruggable' intracellular targets like TDP-43, which is implicated in 97% of ALS cases. Maintained a lean capital structure with zero debt and $308.4 million in cash to support high-value R&D while awaiting long-term partner milestones. Leveraged a 'partnering-first' model for clinical assets, where all current partnered programs originated from Prothena's internal discovery engine. Anticipates up to $105 million in aggregate clinical milestones in 2026, contingent on coramitug enrollment targets and BMS's Phase II decision for PRX019. Plans to implement a share redemption program in 2026 following Irish High Court approval to enhance shareholder value. Focuses on establishing new research collaborations for the CYTOPE platform, targeting therapeutic areas beyond the company's core neuroscience expertise. Expects Phase II TargetTau-1 data from partner BMS in the first half of 2027, serving as a key mid-term catalyst for the Alzheimer's portfolio. Projects primary completion of the pivotal Phase III PARAISO and CLEOPATTRA trials in 2029, representing a potential $3 billion in future milestone eligibility. Modified Phase III PARAISO design to require stable levodopa treatment and extended duration to 24 months to optimize the probability of success based on Phase II learnings. Acknowledged that while PRX012 achieved amyloid negativity in 9 of 12 patients, its safety profile necessitated the shift to TfR technology to remain competitive. Confirmed that the 2026 cash guidance of $50 million to $55 million in usage excludes the potential $105 million in milestone payments. Identified the TDP-43 CYTOPE program as a key differentiator for addressing both toxic gain-of-function and loss-of-function pathology in ALS. Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and...